Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

APTAMER Aktie

>APTAMER Performance
1 Woche: 0%
1 Monat: +200,0%
3 Monate: +200,0%
6 Monate: -25,0%
1 Jahr: -78,6%
laufendes Jahr: -25,0%
>APTAMER Aktie
Name:  APTAMER GROUP LTD LS-,001
Land:  Großbritannien
Sektor:  Gesundheit
ISIN/ Wkn:  GB00BNRRP542 / A3DB1Q
Symbol/ Ticker:  P0J (Frankfurt)
Kürzel:  FRA:P0J, ETR:P0J, P0J:GR
Index:  -
Webseite:  https://aptamergroup.com/
Marktkapitalisierung:  7.75 Mio. EUR
Umsatz:  1.06 Mio. EUR
EBITDA:  -1.95 Mio. EUR
Gewinn je Aktie:  -
Schulden:  0.56 Mio. EUR
Liquide Mittel:  1.71 Mio. EUR
Umsatz-/ Gewinnwachstum:  119.1% / -
KGV/ KGV lG:  - / -
KUV/ KBV/ PEG:  1.08 / 0.99 / -
Gewinnm./ Eigenkapitalr.:  -186.26% / -99.43%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  APTAMER
Letzte Datenerhebung:  05.07.25
>APTAMER Eigentümer
Aktien: 1990 Mio. St.
f.h. Aktien: 1240 Mio. St.
Insider Eigner: 20.74%
Instit. Eigner: 10.14%
Leerverk. Aktien: -
>APTAMER Peer Group

 
04.07.25 - 12:42
IN BRIEF: Aptamer raises £2 million for Optimer commercialisation (Alliance)
 
Aptamer Group PLC - York, England-based biotechnology firm that provides Optimer binders for use in therapeutics, diagnostics, bioprocessing and research - Raises £2.0 million from......
11.06.25 - 15:06
Aptatek BioSciences, Inc. Announces Bridge Financing to Support Advancement of the PheCheck™ Aptamer-based In-home Monitoring Platform (Business Wire)
 
PRINCETON, N.J.--(BUSINESS WIRE)--Aptatek BioSciences, Inc., a pioneer in developing innovative in-home monitoring solutions for patients managing chronic diseases, today announced it has received bridge financing from Canterbury Scientific, Ltd, a current strategic investor. This latest funding tranche follows the successful advancement of Aptatek's PheCheck™ platform, an FDA breakthrough diagnostic device designed for at-home monitoring of phenylalanine levels in patients with phenylketonuria (PKU). The new financing supports Aptatek's ongoing clinical development and accelerates its path toward commercialization of its DNA aptamer-based home monitor for PKU, a genetic metabolic disorder, requiring diligent monitoring of phenylalanine levels to prevent serious health complications. As with diabetes management, maintaining optimal phenylalanine levels through diet and medication is essential for patient health and quality of life. “This further funding from Canterbury Scientific strengthens our abi...
30.05.25 - 17:36
Aptamer signs second Optimer programme contract with Unilever (ShareCast)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
30.05.25 - 11:48
AIM WINNERS & LOSERS: hVIVO shares dive on contract cancellations (Alliance)
 
The following stocks are the leading risers and fallers on AIM on Friday.----------AIM - WINNERS----------Aptamer Group, up 9.0% at 0.37 pence, 12-month range 0.20p-0.90p. The......
30.05.25 - 10:48
Aptamer cheers second product development deal with Unilever (Alliance)
 
Aptamer Group PLC on Friday hailed a 'six-figure' deal with Unilever PLC to develop deodorant products.The York, England-based biotechnology firm provides Optimer binders for use......
15.05.25 - 11:42
AIM WINNERS & LOSERS: Aptamer wins deals; DSW beats market view (Alliance)
 
The following stocks are the leading risers and fallers on AIM on Thursday.----------AIM - WINNERS----------Aptamer Group PLC, up 8.8% at 0.37 pence, 12-month range 0.20p-0.95p.......
07.05.25 - 02:06
Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc. (PR Newswire)
 
AJICAP® Antibody-Drug Conjugate Manufacturing Technology Contributes to Enhanced Efficacy of Antibody Drugs TOKYO, May 7, 2025 /PRNewswire/ -- Ajinomoto Co., Inc. (President: Shigeo Nakamura, Headquarters: Chuo-ku, Tokyo, hereinafter referred to as "Ajinomoto") has been conducting joint......
23.04.25 - 13:42
Zentek Ltd.: Zentek Provides Update on ~$1.1?Million Innovative Solutions Canada Contract to Develop an Avian Influenza Countermeasure Using its Multivalent Aptamer Technology (Accesswire)
 
GUELPH, ON / ACCESS Newswire / April 23, 2025 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), is pleased to announce that it has completed the first phase of the Innovative Solut......
20.03.25 - 13:06
Kiffik Biomedical and Rubix LS Partner to Revolutionize Cancer Diagnostics With Interstitial Fluid and Aptamer Technologies (Accesswire)
 
PROVIDENCE, RI / ACCESS Newswire / March 20, 2025 / Kiffik Biomedical, a leader in interstitial fluid (ISF)-based diagnostics, has announced a strategic partnership with Rubix LS, a pioneer in apta......
10.03.25 - 15:36
UK earnings, trading statements calendar - next 7 days (Alliance)
 
Tuesday 11 March Aptamer Group PLCHalf Year ResultsCostain Group PLCFull Year ResultsDomino's Pizza......
07.03.25 - 17:30
UK earnings, trading statements calendar - next 7 days (Alliance)
 
Monday 10 March Clarkson PLCFull Year ResultsTuesday 11 March Aptamer Group PLCHalf Year Results......
03.01.25 - 13:06
Aptamer signs development contract with biopharmaceutical firm (Alliance)
 
Aptamer Group PLC on December 19 said it signed a new development contract with a rare disease biopharmaceutical company.The York, England-based biotechnology firm providing Optimer......
10.12.24 - 13:48
Aptahem′s Scientific Manuscript now Published in the British Journal of Pharmacology (Cision)
 
Aptahem announced on 10 September 2024 that their scientific manuscript had been accepted for publication in the British Journal of Pharmacology (BJP). On the 9th December 2024, the article has been published. Read the article, titled “Antithrombotic but not anticoagulant activity of the thrombin-binding RNA aptamer Apta-1”, via this link (https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.17382). The article describes the results of the preclinical and mechanistic studies that have been performed by Aptahem and in a collaboration during several years with Örebro University. The study...
09.11.24 - 15:00
Dr Arron Tolley on Aptamer Group′s new optimer developments - ICYMI (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
08.11.24 - 14:12
Aptamer CEO Dr Arron Tolley on extended deal with genetic medicines customer; growing pipeline (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
06.11.24 - 13:31
Zentek and Triera Biosciences Ltd. Receive $1.1 Million Government of Canada Contract to Test Multivalent Aptamer Technology (Accesswire)
 
GUELPH, ON / ACCESSWIRE / November 6, 2024 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), announces that its wholly-owned subsidiary Triera Biosciences Ltd. ("Triera") has recei......
04.09.24 - 09:00
Aptamer extends contract with Unilever (ShareCast)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
03.09.24 - 12:18
Aptamer Group extends Optimer development contract with Unilever (Alliance)
 
Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...
08.07.24 - 12:48
Aptamer says annual revenue halves but hails progress with Unilever (Alliance)
 
Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...
03.07.24 - 12:00
AIM WINNERS & LOSERS: Aptamer rises on AstraZeneca contract (Alliance)
 
Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Kein Kaiser kann, was unser ist, verschenken. - Friedrich Johann Christoph Schiller
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!